 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that ACIU's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

AC Immune SA (ACIU, $3.49) RSI Indicator left the overbought zone on December 05, 2023

AC Immune SA (ACIU, $3.35) RSI Indicator left the overbought zone on December 04, 2023

AC Immune SA (ACIU, $3.4) RSI Indicator left the overbought zone on December 01, 2023

AC Immune appoints Madiha Derouazi as CSO

 Dr. Madiha Derouazi appointed as new CSO of AC Immune

 AC Immune appoints Christopher Roberts as CFO

 Christopher...

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

This is a signal that ACIU's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

AC Immune SA (ACIU, $3.21) Stochastic Oscillator left the overbought zone on November 29, 2023

AC Immune SA (ACIU, $3.03) Stochastic Oscillator left the overbought zone on November 22, 2023

This price move could be a signal that ACIU may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

AC Immune SA (ACIU, $3.19) price may drop as it broke higher Bollinger Band on Nov 20, 2023

AC Immune SA (ACIU Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. W...

Promising Outlook for AC Immune SA: Buy Rating Based on Potential Alzheimer Trials Success and Encouraging ABATE Study Progress

AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Watchers	3,706
52-Wk Low	$1.68
52-Wk High	$3.83

Market Cap	$298.52M
Volume (M)	156,004.00
52-Wk High	$3.83
52-Wk Low	$1.68

Current Price	$3.57
Prev Close	$3.50
Open	$3.50
Dividend Yield	0.00%
50-Day Moving Average	$2.91
Beta	1.19
Avg. Volume	42,182.00
PE Ratio	-4.04

52-Week High	$3.83
52-Week Low	$1.68
Market Capitalization	$298.52M
EPS	-$0.8826
Price to Book	2.04
Revenue Per Employee	$6.65
Enterprise Value/EBITDA	-2.12

ACIU AC Immune SA

About

Feed

News

Sentiment

Earnings

Fundamentals